Liraglutide Market

The Global Liraglutide Market is estimated to be valued at USD 2.38 Bn in 2025 and is expected to decline to USD 1.58 Bn by 2032, exhibiting a negative compound annual growth rate (CAGR) of -5.6% from 2025 to 2032.

The global liraglutide market, once considered a rapidly expanding segment within the diabetes therapeutics landscape, is now experiencing a phase of gradual deceleration, marked by a negative compound annual growth rate (CAGR). This shift is largely attributed to the evolving dynamics in the diabetes care ecosystem, including increased competition from newer-generation GLP-1 receptor agonists, biosimilars, and combination therapies. Liraglutide, a pioneering GLP-1 receptor agonist known for its dual benefits in type 2 diabetes management and weight reduction, continues to hold clinical relevance due to its established efficacy in improving glycemic control and mitigating obesity-related complications. However, its market share is steadily declining as healthcare providers pivot toward newer agents that offer enhanced cardiovascular outcomes, improved tolerability, and more convenient dosing schedules (e.g., once-weekly vs. daily injections). While liraglutide remains a foundational option, especially in legacy treatment protocols, its position is increasingly being challenged by more advanced alternatives.

Market Dynamics

The global liraglutide market's downturn is caused by multiple converging factors. Chief among these is the emergence of superior GLP-1 analogs and dual/triple agonist therapies, which have demonstrated improved clinical outcomes and patient adherence. As healthcare systems worldwide strive to optimize diabetes treatment strategies, these newer agents are being adopted more rapidly, reducing the demand for liraglutide. Moreover, patent expirations have opened the market to biosimilar competition, further compressing margins for originator manufacturers. High treatment costs remain a deterrent, particularly in low- and middle-income markets, where liraglutide's affordability and accessibility are limited. The stringent regulatory landscape and increasing scrutiny over drug safety and efficacy have also hindered expansion into newer indications and markets.

Despite the negative growth trend, niche opportunities persist. These include its continued use in specific patient subgroups, ongoing clinical research into pediatric and adolescent obesity management, and potential incorporation into combination regimens where its unique pharmacokinetic profile offers added value. Additionally, while market growth is stalling in mature regions like North America and Europe, emerging economies with rising diabetes prevalence still represent incremental demand potential, albeit limited. Advancements in formulation, such as oral delivery or depot injections, could revive interest if positioned appropriately. Overall, while liraglutide’s market trajectory reflects a slowdown, it remains a clinically relevant therapy amidst a rapidly shifting treatment paradigm in diabetes and obesity care.

Key features of the study

• This report provides an in-depth analysis of the global liraglutide market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025–2032), considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global liraglutide market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key company covered as a part of this study include Novo Nordisk, Nanjing King-Friend Biochemical Pharmaceutical Co.Ltd, Hikma Pharmaceuticals PLC, Glenmark Pharmaceuticals, Biocon, Teva Pharmaceuticals, Pfizer Inc., and Meitheal Pharmaceuticals
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global liraglutide market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global liraglutide market

Market Segmentation

• Type Insights (Revenue, USD Bn, 2020 - 2032)
• Brand
• Victoza
• Saxenda
• Generic or Biosimilar
• Others (Late Phase Drugs, etc.)
• Indication Insights (Revenue, USD Bn, 2020 - 2032)
• Type 2 Diabetes Mellitus
• Chronic Weight Management or Obesity
• Cardiovascular Disease
• Age Group Insights (Revenue, USD Bn, 2020 - 2032)
• Pediatric (10 years and older)
• Adult
• Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• End User Insights (Revenue, USD Bn, 2020 - 2032)
• Hospitals
• Specialty Clinics
• Outpatient and Primary Care Centers
• Long-Term Care Facilities
• Others (Research and Academic Institutions, etc.)
• Regional Insights (Revenue, USD Bn, 2020 - 2032)
• North America
• U.S.
• Canada
• Latin America
• Brazil
• Argentina
• Mexico
• Rest of Latin America
• Europe
• Germany
• U.K.
• Spain
• France
• Italy
• Russia
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• GCC Countries
• Israel
• Rest of Middle East
• Africa
• South Africa
• North Africa
• Central Africa
• Key Players Insights
• Novo Nordisk
• Nanjing King-Friend Biochemical Pharmaceutical Co.Ltd
• Hikma Pharmaceuticals PLC
• Glenmark Pharmaceuticals
• Biocon
• Teva Pharmaceuticals
• Pfizer Inc.
• Meitheal Pharmaceuticals

Show more